Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma

Nobufumi Sekino | Masayuki Kano | Yasunori Matsumoto | Haruhito Sakata | Yasunori Akutsu | Naoyuki Hanari | Kentaro Murakami | Takeshi Toyoizumi | Masahiko Takahashi | Ryota Otsuka | Masaya Yokoyama | Tadashi Shiraishi | Koichiro Okada | Isamu Hoshino | Keiko Iida | Aki Komatsu Akimoto | Hisahiro Matsubara

Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that has proven difficult to treat despite multidisciplinary therapy, and a new treatment strategy is demanded. Metformin is used for type 2 diabetes mellitus and its antitumor effects have been reported recently. Metformin exerts antitumor effects in various respects, such as inhibiting inflammation, tumor growth and epithelial-mesenchymal transition (EMT). However, few reports have described the efficacy of metformin on ESCC, and their findings have been controversial. We analyzed the antitumor effects of metformin and clarified its effects on anti-inflammation, growth suppression and EMT inhibition. Activation of nuclear factor kappa B (NF-κB), the major transcription factor induced by inflammation, was investigated by immunostaining. We found that localization of NF-κB in the nucleus was reduced after metformin treatment. This suggests that metformin inhibited the activation of NF-κB. Metformin inhibited tumor growth and induced apoptosis in ESCC cell lines. Associated with EMT, we examined cell motility by a wound healing assay and the epithelial marker E-cadherin expression of various ESCC cell lines by western blotting. Metformin inhibited cell motility and induced E-cadherin expression. In conclusion, metformin showed multiple antitumor effects such as growth suppression, invasion inhibition, and control of EMT by inhibiting NF-κB localization on ESCC. Further exploration of the marker of treatment efficacy and combination therapy could result in the possibility for novel treatment to use metformin on ESCC.

KEYWORDS
epithelial-mesenchymal transition, esophageal squamous cell carcinoma, inflammation, metformin, treatment outcome

Abbreviations: AMPK, AMP-activated kinase; DM, diabetes mellitus; EMT, epithelial mesenchymal transition; ESCC, esophageal squamous cell carcinoma; LKB1, liver kinase B1; NF-κB, nuclear factor-kappa B; TGF-β, transforming growth factor-beta.
Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that shows a high incidence in East Asia. It remains difficult to treat despite multidisciplinary therapy, including surgery, chemotherapy, and radiotherapy. In particular, tolerance to chemotherapy and a tendency toward metastasis even when tumors are superficial are major factors making treatment difficult.\(^1\) We have recently been conducting research focused on epigenetics and reported that microRNA-375 induced by histone acetylation had ESCC restraint activity.\(^2\) We searched drugs which induce similar gene expression style by connectivity map and found metformin. It restrained the increase of ESCC cell lines, TE2 and T.Tn.\(^3\)

Metformin is an oral biguanide that has been used to treat type 2 DM worldwide for a long time, and the antitumor effects of metformin have been reported recently.\(^4\) The main target of metformin is regarded as AMPK, which has various functions. Metformin induces the activation of LKB1, which phosphorylates and activates AMPK.\(^5\) However, details on the drug’s activities remain unclear.

DM increases the risk of developing cancer, and possible biological links between DM and cancer comprise hyperinsulinemia, hyperglycemia and fat-induced chronic inflammation.\(^6\) Patients treated with metformin have shown a lower incidence of cancer than the other treatment groups.\(^7\) In addition, metformin reportedly affects various cancers, such as gastric cancer,\(^8\) non-small cell lung cancer,\(^9\) and colorectal cancer.\(^10\) Metformin exerts its antitumor effects in various ways, including inducing cell cycle arrest,\(^11\) enhancing the immune system,\(^12\) inhibiting EMT,\(^13\) inducing hypersusceptibility for chemotherapy,\(^14\) and inhibiting inflammatory signals through NF-κB/TGF-β.\(^15\)

Epithelial-mesenchymal transition (EMT) plays a key role in inducing stationary tumor cells to migrate and invade and metastasize to other organs.\(^16\) E-cadherin is the most important marker of epithelial cells and is used widely to determine EMT inhibition.\(^17\) It has recently been shown that metformin inhibits migration or invasion by affecting EMT in various tumors, such as cholangiocarcinoma,\(^18\) cervical carcinoma,\(^19\) thyroid cancer\(^20\) and melanoma.\(^21\)

Regarding the clinical antitumor effects of metformin on ESCC, Van De Voorde reported that the use of metformin was associated with an improved overall and distant metastasis-free survival rate in patients with esophageal cancer.\(^22\) In contrast, Spierings reported that metformin use in patients receiving neoadjuvant chemoradiotherapy for potentially curable esophageal cancer did not show better outcomes of pathological response rates or an improved overall or disease-free survival rate.\(^23\) The antitumor effect of metformin on ESCC remains controversial. Few reports have examined the mechanism underlying the antitumor effect of metformin on ESCC.

It has already been reported that metformin affects tumor growth in ESCC through cell cycle arrest.\(^24,25\) Furthermore, one report described the effect of EMT inhibition in ESCC, outlining the inhibitory effects of radiation exposure for EMT through TGF-β signaling.\(^26\) These reports suggest that metformin has effects on growth inhibition as well as EMT inhibition, which is associated with invasion and metastasis, and enhancement of chemotherapy sensitivity. However, few reports have found that metformin affects EMT in ESCC, and the results of such studies are eagerly awaited.

Given the above, we analyzed the antitumor effect of metformin, including anti-inflammation, growth suppression and EMT inhibition, and explored the mechanisms by which such effects are achieved.

## MATERIALS AND METHODS

### 2.1 ESCC cell culture and reagents

Human ESCC cell lines were cultured in DMEM/Nutrient Mixture F-12 Ham (Sigma-Aldrich, St Louis, MO, USA) with 10% FBS in a humidified incubator at 37°C in a 5% CO₂. We used the human ESCC cell lines TE1, TE2, TE4, TE5, TE6, TE8, TE10, TE11, TE14, TE15 and T.Tn. We also used TE2-fluorescent ubiquitination-based cell cycle indicator (Fucci) cells. T.Tn cells were provided by the Japanese Cancer Research Resources Bank. TE1, TE2, TE4, TE5, TE6, TE8, TE10, TE11, TE14 and TE15 cells were kindly provided by Dr T. Nishihira (Tohoku University, Sendai, Japan).

Metformin was obtained from Sigma Chemical Co. (St Louis, MO, USA). Penicillin and streptomycin were obtained from North China Pharmaceutical Group Corp (Shijiazhuang, China). We obtained 0.05% trypsin-EDTA and FBS from Invitrogen Life Technologies (Danvers, MA, USA). Antibodies against AMPK and LKB1 were purchased from Cell Signaling Technology (Danvers, MA, USA), that against E-cadherin was purchased from Santa Cruz Biotechnology (Dallas, TX, USA), that against NF-κB p65 and β-actin were purchased from Abcam (Cambridge, UK), and a rabbit-secondary antibody was purchased from Invitrogen.

### 2.2 Cell viability assay

The inhibitory influence of cell proliferation by giving metformin was evaluated by cell viability using Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). Cells were seeded in 96-well plates at 5 × 10^3 cells per well and cultured for 24 hours. Then the cells were exposed to various concentrations of metformin for 72 hours, and the antiproliferative effects were determined using a CCK-8. Absorbance was determined at 450 nm using a microplate reader.

### 2.3 Tumor xenograft model

Six-week-old Balb/c nude mice were used to establish a TE2-FUCCI and TE14 tumor model. Nude mice were housed in a specific-pathogen-free facility. TE2-FUCCI and TE14 cells were harvested and injected s.c. into the dorsal area at 5 × 10^6 cells. The mice were randomized into a control group and a treatment group (TE2-FUCCI: 7 mice per group, and TE14: 6 mice per group). After 14 days, tumors became palpable, and mice in the treatment group were given metformin (5 mg/mice) by ip, injection, whereas those in the control group were given PBS (100 μL) 5 times a week. Treatments
were carried out for 28 days, and tumor volumes (volume = 0.5 × width² × length) were determined regularly.

2.4 Apoptosis in vivo

Tumor tissues were embedded in paraffin and then sectioned at 4 μm and deparaffinized. Apoptosis was detected based on an analysis of DNA fragmentation using a TUNEL with an In situ Apoptosis Detection kit (Takara, Tokyo, Japan). The apoptotic index was defined as the number of positive cells among TE2-FUCCI tumor xenograft models in arbitrary microscopic fields (6 mice per group).

2.5 Western blotting

Antihuman LKB1 mouse monoclonal IgG and antihuman AMPK mouse monoclonal IgG and antihuman E-cadherin rabbit polyclonal IgG were used as primary antibodies. Cells were harvested with the indicated concentrations of metformin for 24 hours and lysed with radioimmunoprecipitation assay (RIPA) buffer. Western blot analysis was done on an XV PANTERA Gel 7.5%-15% (DRC, Tokyo, Japan). Proteins in the gels were transferred electrophoretically onto nitrocellulose membranes. The membranes were incubated with primary antibodies against NF-κB p65, LKB1, AMPK, E-cadherin and β-actin. Expression of each protein was detected using secondary antibodies conjugated to peroxidase-labeled polymers. Bands were visualized using the Amersham ECL Prime Western blotting reagent (GE Healthcare Life Sciences, Uppsala, Sweden). Densitometry was done using the ImageJ software program (NIH, Bethesda, MD, USA).

2.6 Wound healing assay

T.Tn and TE2-FUCCI cells were scratched after metformin treatment for 24 hours, harvested with the same concentration of metformin, and photographed digitally at 0 and 22 hours from scratch. The intercellular space was measured at random, and the relative value was calculated on the basis of the gap at the time when the cells were scratched.

2.7 Cell migration and invasion assays

TE2, TE14 and T.Tn cells were used in cell migration and invasion assays. The cell migration assay was carried out using a micropore membrane filter with 8-μm pores (BD Biosciences). The collagen I-coated chambers were prepared as described previously. Procedures of cell seeding and attractant addition were the same as in the cell migration assay, and the membrane was fixed and trained after 48 hours.

Cell migration/invasion was quantified by counting the average number of migrated/invaded cells in random high-powered fields per filter.

2.8 Fluorescence microscopy

TE2 cells cultured on coverslips were fixed in 4% paraformaldehyde for 10 minutes and permeabilized with 0.1% Triton X-100 for 5 minutes. After blocking with 3% FBS/PBS, cells were incubated with antihuman NF-κB p65 rabbit antibody at 37°C for 60 minutes. The cells were then incubated with Alexa Fluor 488 goat antirabbit IgG (Invitrogen) as the secondary antibody. Pro-Long Gold antifade reagent with DAPI (Invitrogen) was used for counterstaining of DNA.

2.9 Statistical analyses

Data were analyzed by t tests conducted using the Excel software program (Microsoft, Redmond, WA, USA). P < .05 was considered to indicate significance.

3 RESULTS

3.1 NF-κB activity

Effect of metformin on the expression and intracellular localization of NF-κB on TE2 cells was examined. Total protein expression of NF-κB was decreased by giving metformin at ≥0.3 mmol/L (Figure 1A). Intracellular localization of NF-κB was evaluated by immunostaining (Figure 1B). NF-κB existed in both the cytoplasm and the nucleus in the control group, but NF-κB expression in the nucleus was lower in the group treated with 0.3 mmol/L metformin for 24 hours (Figure 1C). These results suggest that metformin affects the nuclear import of NF-κB, and inhibits activating NF-κB signaling.

3.2 Growth inhibition

3.2.1 Proliferation assay and AMPK and LKB1 protein expression in ESCC cell lines

Metformin inhibited cell proliferation in all ESCC cell lines (TE1, TE2, TE4, TE5, TE6, TE8, TE10, TE11, TE14, TE15 and T.Tn) in a dose-dependent way. However, there was a marked difference in the sensitivity among these cell lines (Figure 2A). AMP-activated kinase (AMPK) and LKB1 protein expression as evaluated by western blotting in the steady state varied among cell lines. However, there was no significant correlation between their expression and metformin sensitivity (Figure 2B).
3.2.2 Tumor growth and apoptosis in vivo

Relative tumor volume was significantly smaller in the metformin-treated group than in the control group in both TE2-FUCCI (\(P = .033\)) (Figure 3A) and TE14 cell lines (\(**P = .031\)) (Figure 3B). There was no marked difference in bodyweight change of the mice in the control group and in the metformin-treated group for both TE2-FUCCI (Figure 3C) and TE14 (Figure 3D). In the TE2-FUCCI xenograft model, apoptotic cells were detected by TUNEL stain (brown nuclear cells: positive cells; green nuclear cells: negative), and there were significantly more apoptotic cells in the tumors in the metformin-treated group than in the control group (\(P = .0257\)) (Figure 3E,F).

3.3 EMT inhibition

Epithelial-mesenchymal transition (EMT) is associated with malignancy and increased cell motility, based on migration and invasion ability. The wound healing assay and cell migration/invasion assay were useful for evaluating cell motility.

3.3.1 Wound healing assay

Cell migration in the high-concentration metformin-treated group (5 or 10 mmol/L) was significantly lower than in the control group, but the migration in the low-concentration metformin-treated group (1 or 3 mmol/L) did not show a significant difference from the control group (Figure 4A,B). These results suggest that metformin inhibited TE2-FUCCI and T.Tn cell motility in a dose-dependent way. Furthermore, a larger proportion of cells were in G0/G1 in the high-concentration metformin-treated group than in the control group.

3.3.2 Cell migration/invasion assay

In the migration assay, the number of cells penetrating the membrane of TE2 cells was significantly and dose-dependently decreased by metformin (Figure 5A; \(*P = .01\) for 0 vs 3 mmol/L and \(**P = .01\) for 0 vs 5 mmol/L). In contrast, the number of cells penetrating the membrane was slightly less but not significantly so for T.Tn cells (Figure 5B; \(*P = .88\) for 0 vs 3 mmol/L and \(**P = .16\) for 0 vs 5 mmol/L).
In the invasion assay, the number of cells penetrating the TE2 cell membrane coated with collagen-I was also decreased by metformin in a dose-dependent way (Figure 5C; *P = .23 for 0 vs 3 mmol/L and **P = .04 for 0 vs 5 mmol/L). In contrast, the number of cells penetrating the membrane was slightly less but not significantly so for T.Tn cells (Figure 5D; *P = .18 for 0 vs 3 mmol/L and **P = .13 for 0 vs 5 mmol/L).

Giving metformin significantly decreased the migration/invasion ability of TE2 cells, but this tendency was not clearly observed in T.Tn cells.

3.3.3 | E-cadherin expression

E-cadherin is expressed by epithelial cells and so is an important marker of EMT. We first evaluated the effect of metformin on the induction of E-cadherin expression by western blotting. In TE2 cells, metformin induced E-cadherin protein expression in a dose-dependent manner (Figure 6A). In TE14 cells, metformin did not increase the expression of E-cadherin (Figure 6B). Finally we examined E-cadherin expression in TE1, TE4, TE5, TE6, TE8, and TE11 cells. In TE1, TE8 and TE11...

**FIGURE 2** Proliferation assay and AMP-activated kinase (AMPK) and liver kinase B1 (LKB1) protein expression in esophageal squamous cell carcinoma (ESCC) cell lines. A, Proliferation assay using Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). Metformin was given to ESCC cells for 72 h. B, Western blotting analysis of AMPK and LKB1 protein expression at steady state in these ESCC cell lines.

**FIGURE 3** Tumor growth and apoptosis in vivo. Relative tumor volume in the xenograft model of (A) TE2-FUCCI (n = 7) and (B) TE14 (n = 6). In both the TE2-FUCCI and TE14 models, relative tumor volume was significantly smaller in the metformin-treated group than in the control group (TE2-FUCCI: *P = .033, TE14: **P = .031). Bar, SE. Bodyweight of the xenograft model at days 14 and 42 after the injection of (C) TE2-FUCCI (n = 7) and (D) TE14 (n = 6) is shown. There were no significant differences between the control group and the metformin-treated group. Bar, SD. E, In the TE2-FUCCI xenograft model, the apoptotic cells were detected by TUNEL stain (brown nuclear cell: positive; green nuclear cell: negative). F, Average number of apoptotic cells per view in the TE2-FUCCI xenograft model (n = 6). There were significantly more apoptotic cells in the tumors in the metformin-treated group than in the control group (*P = .0257). Bar, SD...
FIGURE 4 Wound healing assay. A, T.Tn and TE2-FUCCI cells were treated with metformin and captured after 22 h from scratch. Magnification, ×200. Relative distance of the intracellular space is shown (n = 7). Bar, SD. Cell strains: (B) T.Tn, (C) TE2-FUCCI.

| Metformin (mmol/L) | 0 h | 22 h |
|--------------------|-----|------|
| 0 mmol/L           | ![Image](image1.png) | ![Image](image2.png) |
| 1 mmol/L           | ![Image](image3.png) | ![Image](image4.png) |
| 3 mmol/L           | ![Image](image5.png) | ![Image](image6.png) |
| 5 mmol/L           | ![Image](image7.png) | ![Image](image8.png) |
| 10 mmol/L          | ![Image](image9.png) | ![Image](image10.png) |

FIGURE 5 Cell migration/invasion assay. A cell migration assay was carried out. The migrating cells were fixed and stained at 24 h after seeding. A, TE2 cells, *P = .01 (0 vs 3 mmol/L), and **P = .01 (0 vs 5 mmol/L). B, T.Tn cells, *P = .88 (0 vs 3 mmol/L), and **P = .16 (0 vs 5 mmol/L). A cell invasion assay was carried out. The invading cells were fixed and stained at 48 h after seeding. C, TE2 cells, *P = .23 (0 vs 3 mmol/L), and **P = .04 (0 vs 5 mmol/L). D, T.Tn cells, *P = .18 (0 vs 3 mmol/L), and **P = .13 (0 vs 5 mmol/L).
cells, E-cadherin expression was increased, but the other ESCC cell lines did not show a similar tendency (Figure 6C).

4 | DISCUSSION

In the present study, we found that metformin affected tumor malignancy through action on tumor growth and EMT, and these effects may have been induced by inhibiting NF-κB activity. Cell cycle arrest and TGF-β signaling have already been reported as antitumor mechanisms of metformin, but NF-κB also participates in the antitumor effects of metformin.

It has been reported that metformin inhibits cell proliferation on ESCC cell lines, but our evaluation of the effects on proliferation of various ESCC cell lines showed that metformin sensitivity varied among cell lines. Surprisingly, there was no significant correlation between metformin sensitivity and expression of AMPK or LKB1. Other determinatives and various molecular functions may influence metformin sensitivity of cancer cells. Although the main target of metformin is thought to be AMPK, it reportedly also acts on other pathways, such as the MAPK pathway and NF-κB. These pathways may also be activated by metformin apart from AMPK activation. Whether or not the antitumor effect of metformin differs depending on the cancer type remains unclear, but the answer may involve the pathway that is more likely to be activated.

It has been reported that tumor growth is inhibited and apoptosis is induced by metformin in vivo and, in our study, a similar tendency was shown. Furthermore, TE14 cells were more sensitive to metformin than TE2 cells in vitro, and the tumor size of TE14 cells was smaller than that of TE2-FUCCI cells. Metformin sensitivity may therefore be correlated in vitro and in vivo.

Based on these in vitro and in vivo results, metformin appears to affect tumor size by inhibiting cell proliferation and inducing apoptosis.

Expression of E-cadherin, the most important marker of epithelial cells, was induced by metformin in various ESCC lines, but sensitivity to metformin differed among those cell lines. Expression of LKB1 or AMPK did not show clear correlations with metformin sensitivity. As mentioned earlier, this result also suggests that other factors may exist that influence the sensitivity to metformin.

Various reports have examined the mechanisms by which metformin affects EMT, such as through TGF-β or mammalian target of rapamycin (mTOR). It has also been reported that NF-κB induced EMT and reduced E-cadherin expression. NF-κB is an important nuclear factor that is associated with various physiological phenomena, including acute or chronic inflammation, cell proliferation, suppressing apoptosis, and the immune response. NF-κB is known to be constantly active in many malignant tumors and is a central signaling hub in inflammation-mediated tumor promotion and metastasis. In ESCC, clinical correlation of NF-κB expression and prognosis has been examined, and ESCC patients with NF-κB-positive tumors have shown poor survival.

Because metformin exerts multiple effects, including inhibiting tumor growth and EMT and inducing apoptosis, correlation of metformin and NF-κB, which also has various physiological functions, has received attention. There are some reports that metformin inhibits NF-κB in several cancers, such as pancreatic tumor, bladder cancer, and cholangiocarcinoma. This is the first report to find that metformin inhibits NF-κB in ESCC. Carcinogenesis occurs in multiple phases as tumor initiation, promotion and progression. NF-κB induces inflammation, which is a very important aspect of tumor promotion. Therefore, metformin may inhibit tumor promotion by inactivating NF-κB.

There are many signals that are associated with EMT. Transforming growth factor-beta (TGF-β), which strongly promotes EMT, was reported to be inhibited by metformin in ESCC cell lines. However, in our study, mRNA expression of TGF-β showed no significant
change on treatment with metformin (data not shown), suggesting that some other EMT-inducing signal is likely inhibited by metformin. Change in intracellular localization of NF-κB by metformin may show that metformin exerts its antitumor effect by inhibiting EMT through NF-κB.

As is often pointed out, the concentration at which metformin exerts its effects differs between in vivo and in vitro. We reported that 5 mg/mouse (250 mg/kg) of metformin was given to mice, giving a blood concentration of metformin of 5 μmol/L. The blood concentration of metformin in patients taking metformin is reported to be 10 μmol/L. The metformin concentration that showed an effect in vitro was much higher than that showing an effect in vivo. Therefore, we must confirm whether or not the results obtained in vitro reflect the effects in vivo. Differences in the metformin concentration can result in a high glucose concentration in the medium. It has been reported that the concentration of glucose in solid tumor is ≤0.5 mmol/L, and cells cultured at low glucose concentrations have greater metformin sensitivity for cell viability than those cultured at high glucose concentrations. As a result, metformin may act specifically on solid tumor cells instead of on normal cells, and a high glucose concentration may mask the antitumor effects of metformin to some extent in vitro.

Although the concentration of metformin given was higher than that delivered in vivo, the antitumor effects that metformin showed in vitro in this report seem sufficient to result in the same outcome in vivo, as these effects were recognized even under the influence of high glucose concentrations. In this report, medium with a normal glucose concentration was used, but medium with a low glucose concentration may be more suitable for examining the antitumor effect in vivo.

In our study, metformin showed antitumor effects by inhibiting cell proliferation, tumor growth and EMT and inducing apoptosis in ESCC in vitro. The effects of metformin on cell proliferation, tumor growth and EMT differ specifically between in vivo and in vitro. We reported that delivered in vivo, the antitumor effects that metformin showed to some extent in vitro.

The high glucose concentration may mask the antitumor effects of metformin. It has been reported that the concentration of glucose in solid tumor can result in a high glucose concentration in the medium. Therefore, we must confirm whether or not the results obtained in vitro reflect the effects in vivo. Differences in the metformin concentration can result in a high glucose concentration in the medium. It has been reported that the concentration of glucose in solid tumor is ≤0.5 mmol/L, and cells cultured at low glucose concentrations have greater metformin sensitivity for cell viability than those cultured at high glucose concentrations. As a result, metformin may act specifically on solid tumor cells instead of on normal cells, and a high glucose concentration may mask the antitumor effects of metformin to some extent in vitro.

In our study, metformin showed antitumor effects by inhibiting cell proliferation, tumor growth and EMT and inducing apoptosis in ESCC cell lines and xenograft models. These effects may have been induced by inhibiting NF-κB activation on ESCC. Therefore, metformin may be useful for treating ESCC, and further studies are expected.

CONFLICTS OF INTEREST

Authors declare no conflicts of interest for this article.

ORCID

Nobufumi Sekino https://orcid.org/0000-0002-7705-036X

REFERENCES

1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400-412.
2. Isozaki Y, Hoshino I, Nohata N, et al. Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. Int J Oncol. 2012;41:985-994.
3. Isozaki Y, Hoshino I, Akutsu Y, et al. Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map. Oncology. 2014;87:351-363.
4. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE. 2012;7:e33411.
5. Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S. Metformin: its emerging role in oncology. Hormones (Athens). 2011;10:5-15.
6. Wojciechowska J, Krajewski W, Bolanowski M, Krecicki T, Zatonski T. Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016;124:263-275.
7. Currie JF, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-1777.
8. Chen G, Feng W, Zhang S, et al. Metformin inhibits gastric cancer cell proliferation and induces apoptosis via the inhibition of HIF1alpha/PKM2 signaling. Am J Cancer Res. 2015;5:1423-1434.
9. Guo Q, Liu Z, Jiang L, et al. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase. Mol Med Rep. 2016;13:2590-2596.
10. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a meta-analysis. Pharm Biol. 2016;54:2636-2642.
11. Zhuang Y, Miskimins WK. Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008;3:18.
12. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a meta-analysis. Mol Med Rep. 2016;13:2590-2596.
13. Zhao Z, Cheng X, Wang Y, et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS ONE. 2014;9:e95884.
14. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507-7511.
15. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507-7511.
16. Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11:28-39.
17. Lee JY, Kong G. Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression. Cell Mol Life Sci. 2016;73:4643-4660.
18. Trinh SX, Nguyen HT, Saimuang K, Prachayasittikul V, Chan On W. Metformin inhibits migration and invasion of cholangiocarcinoma cells. Asian Pac J Cancer Prev. 2017;18:473-477.
19. Cheng K, Hao M. Metformin inhibits TGF-beta1-induced epithelial-to-mesenchymal transition via PKM2 relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells. Int J Mol Sci. 2016;17:2000.
20. Tan XL, Bhattacharyya KK, Dutta SK, et al. Metformin suppresses pancreatic tumor growth with inhibition of NFkappaB/STAT3 inflammatory signaling. Pancreas. 2015;44:636-647.
21. Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11:28-39.
22. Lee JY, Kong G. Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression. Cell Mol Life Sci. 2016;73:4643-4660.
23. Trinh SX, Nguyen HT, Saimuang K, Prachayasittikul V, Chan On W. Metformin inhibits migration and invasion of cholangiocarcinoma cells. Asian Pac J Cancer Prev. 2017;18:473-477.
24. Cheng K, Hao M. Metformin inhibits TGF-beta1-induced epithelial-to-mesenchymal transition via PKM2 relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells. Int J Mol Sci. 2016;17:2000.
25. Han B, Cui H, Kang L, et al. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway. Tumour Biol. 2015;36:6295-6304.
26. Liang G, Ding M, Lu H, et al. Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration. Oncol Lett. 2015;10:1527-1532.
27. Van De Voorde L, Janssen L, Larue R, et al. Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer? Eur J Surg Oncol. 2015;41:1333-1339.
28. Spierings LE, Lagarde SM, van Oijen MG, et al. Metformin use during treatment of potentially curable esophageal cancer patients is not associated with better outcomes. Ann Surg Oncol. 2015;22(suppl 3):S766-S771.
24. Cai X, Hu X, Tan X, et al. Metformin induced AMPK activation, G0/G1 phase cell cycle arrest and the inhibition of growth of esophageal squamous cell carcinomas in vitro and in vivo. PLoS ONE. 2015;10: e0133349.

25. Tang JC, An R, Jiang YQ, Yang J. Effects and mechanisms of metformin on the proliferation of esophageal cancer cells in vitro and in vivo. Cancer Res Treat. 2017;49:778-789.

26. Nakayama A, Ninomiya I, Harada S, et al. Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma. Int J Oncol. 2016;49:1890-1898.

27. Wang FQ, Ariztia EV, Boyd LR, et al. Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecol Oncol. 2010;117:88-95.

28. Lei Y, Yi Y, Liu Y, et al. Metformin targets multiple signaling pathways in cancer. Chin J Cancer. 2017;36:17.

29. Wang F, He W, Fanghui P, Wang L, Fan Q. NF-kappaB5 promotes invasion and metastasis of esophageal squamous cell cancer by regulating matrix metalloproteinase-9 and epithelial-to-mesenchymal transition. Cell Biol Int. 2013;37:780-788.

30. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-759.

31. Xia Y, Shen S, Verma IM. NF-kappaB, an active player in human cancers. Cancer Immunol Res. 2014;2:823-830.

32. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Ann Rev Immunol. 2009;27:693-733.

33. Bollrath J, Greten FR. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep. 2009;10:1314-1319.

34. Hatata T, Higaki K, Tatebo S, Shomori K, Ikeguchi M. Immunohistochemical study of nuclear factor-kappaB expression in esophageal squamous cell carcinoma: prognostic significance and sensitivity to treatment with 5-FU. Dis Esophagus. 2012;25:716-722.

35. Choi BH, Lee DH. Controls of nuclear factor-kappa B signaling activity by 5’-AMP-activated protein kinase activation with examples in human bladder cancer cells. Int Neurourol J. 2016;20:182-187.

36. Saengboonn M, Seubwai W, Cha’On U, Sawanyawisuth K, Wongham S, Wongkham C. Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-kB. Anticancer Res. 2017;37:115-123.

37. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178-196.

38. Chandel NS, Avizioso D, Rezcek CR, et al. Are metformin doses used in murine cancer models clinically relevant? Cell Metab. 2016;23:569-570.

39. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98.

40. Schroeder T, Yuan H, Viglianti BL, et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res. 2005;65:5163-5171.

41. Yu H, Bian X, Gu D, He X. Metformin synergistically enhances cisplatin-induced cytotoxicity in esophageal squamous cancer cells under glucose-deprivation conditions. Biomed Res Int. 2016;2016:8678634.